PEACHI header v5 FP7-gen-RGB EU flag

Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections

A collaborative project financed by the EC Framework Programme 7

News

PEACHI-03 Clinical Trial Update

 

Following the completion of Work Package 1 (Production of clinical lots and approval for use in clinical trials), work has begun on PEACHI-03 (safety and immunogenicity of second generation viral vectored technology using ChAd3 and MVA, employing NSmut linked to the human MHC class II invariant chain, in both healthy subjects and HIV-positive patients).

 

The protocol for the healthy volunteer and DAA-treated patient arms has been completed and currently is under review by the relevant UK regulatory bodies.   Recruitment is scheduled to begin in October.

 

PEACHI-04 Clinical Trial Update

 

The final volunteer visit has now taken place for clinical trial PEACHI-04 (evaluation of the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines).

 

PEACHI-02 Clinical Trial Update

 

Recruitment of 20 participants for the clinical trial PEACHI-02 (evaluation of the safety and immunogenicity of prime-boost immunisations with candidate HCV vaccines in HIV seropositive individuals) at both trial sites, St James's Hospital Dublin, Ireland and Kantonsspital St. Gallen, Switzerland is now complete.

 

Annual Meeting

 

The 3rd PEACHI annual meeting was held in Dublin, Ireland on 23-24th May 2016. The meeting gave researchers an excellent opportunity to discuss progress made on the project during Year Three and plans for Year Four, as well as plans for a no cost exention to the project.

 

Archive

 

PEACHI-02 Clinical Trial Update

 

Recruitment has now commenced for the clinical trial PEACHI-02 (evaluation of the safety and immunogenicity of prime-boost immunisations with candidate HCV vaccines in HIV seropositive individuals) at both trial sites, St James's Hospital Dublin, Ireland and Kantonsspital St. Gallen, Switzerland.

 

 

PEACHI-04 Clinical Trial Update

 

Approximately 50% of participants have been recruited for PEACHI-04 (evaluation of the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines). For more information click here.

 

Annual Meeting

 

The 2nd PEACHI annual meeting was held in Rome, Italy on 19th - 20th May 2015. The meeting gave researchers an excellent opportunity to discuss progress made on the project during Year Two and plans for Year Three.

 

PEACHI-02 Clinical Trial

Ethical and regulatory approvals have been obtained for the clinical trial PEACHI-02 (evaluation of the safety and immunogenicity of prime-boost immunisations with candidate HCV vaccines in HIV seropositive individuals). Recruitment is due to commence at the trial sites in June 2015.

 

10/10/14: PEACHI-04 Trial Initiation

Recruitment has commenced for the clinical trial PEACHI-04 (evaluation of the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines).